Using a commercial Hereditary Cancer Risk Test on 12/31/16, no mutations were identified in 31 DNA homologous or mismatch repair genes, including BRCA1/2, ATM, POLD1/POLE, RAD51D, TP53, NBN, PALB2, PMS2, MLH1, MSH2, MSH6, MYTYH, and EpCAM. In addition, immunohistochemistry analysis of his prostate biopsy did not reveal loss of MLH1, MSH2, MSH6, or PMS2, and his tumor was found to be microsatellite stable. This evidence concerns the gene MLH1 and neoplasm.